Su Henry K, Ozbek Umut, Likhterov Ilya, Brant Jason, Genden Eric M, Urken Mark L, Chai Raymond L
Thyroid, Head and Neck Cancer (THANC) Foundation, The Mount Sinai Hospital, New York, New York.
Department of Population Health Science and Policy, The Mount Sinai Hospital, New York, New York.
Laryngoscope. 2016 Nov;126(11):2484-2491. doi: 10.1002/lary.26024. Epub 2016 May 31.
OBJECTIVES/HYPOTHESIS: Minimally invasive transoral surgical approaches for the resection of oropharyngeal tumors offer unique opportunities to achieve oncologically sound results while reducing treatment-related morbidity. The objective of this study is to characterize the mortality and complication rates of transoral oncologic resections in a large, prospective, de-identified national dataset from multiple hospitals. STUDY DESIGN: Retrospective, multi-institutional cohort study of 305 patients. METHODS: The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) datasets were accessed and examined for adult patients who underwent transoral surgical resection of oropharyngeal cancers during the years 2010 through 2013. Patient demographics, postoperative complications, and 30-day mortality were evaluated. RESULTS: A total of 305 patients in the 2010 to 2013 ACS NSQIP datasets met study criteria. For the 18 postoperative complications that we assessed, 24 of 305 patients developed 37 complications, representing a complication rate of 7.9%. Among all patients, the 30-day mortality rate was 0.7%, representing two patient deaths. The presence of preoperative dyspnea, hypertension requiring medication, and an American Society of Anesthesiologists classification of 3 or 4 were significantly associated with extended hospital length of stay (LOS) (> 4 days). On multivariate analysis, hypertension was the only factor that was marginally significant with a longer LOS (odds ratio = 1.74, P = 0.057). CONCLUSION: Transoral resection of properly selected oropharyngeal tumors is safe, with low 30-day morbidity and mortality. A greater understanding of the risk factors for complications following transoral surgery may improve patient selection and safety. LEVEL OF EVIDENCE: 4. Laryngoscope, 126:2484-2491, 2016.
目的/假设:用于切除口咽肿瘤的微创经口手术方法为实现肿瘤学上合理的结果提供了独特机会,同时可降低治疗相关的发病率。本研究的目的是在一个来自多家医院的大型、前瞻性、去识别化的全国数据集中,描述经口肿瘤切除术的死亡率和并发症发生率。 研究设计:对305例患者进行的回顾性、多机构队列研究。 方法:获取并检查美国外科医师学会国家外科质量改进计划(ACS NSQIP)数据集,以了解2010年至2013年期间接受口咽癌经口手术切除的成年患者情况。评估患者人口统计学、术后并发症和30天死亡率。 结果:2010年至2013年ACS NSQIP数据集中共有305例患者符合研究标准。对于我们评估的18种术后并发症,305例患者中有24例发生了37种并发症,并发症发生率为7.9%。在所有患者中,30天死亡率为0.7%,即2例患者死亡。术前呼吸困难、需要药物治疗的高血压以及美国麻醉医师协会分级为3或4与延长住院时间(>4天)显著相关。多因素分析显示,高血压是唯一与住院时间延长有边缘显著性的因素(比值比=1.74,P=0.057)。 结论:对口咽肿瘤进行适当选择后的经口切除是安全的,30天发病率和死亡率较低。对口咽手术后并发症危险因素的更深入了解可能会改善患者选择和安全性。 证据水平:4。《喉镜》,126:2484 - 2491,2016年。
Laryngoscope. 2014-11
J Otolaryngol Head Neck Surg. 2015-9-30
JAMA Otolaryngol Head Neck Surg. 2013-8-1
Eur Arch Otorhinolaryngol. 2015-1
Curr Oncol Rep. 2018-1-19
Eur Arch Otorhinolaryngol. 2017-8